<DOC>
	<DOCNO>NCT01787864</DOCNO>
	<brief_summary>We propose tissue sample collection study patient UNC undergone undergo radiofrequency ablation therapy Barrett 's Esophagus ( BE ) intramucosal adenocarcinoma part routine medical care . Purpose : To determine prevalence metaplasia dysplasia gastric cardia ablative therapy . To determine incidence cardiac metaplasia dysplasia function ablative therapy . To determine correlation dysplasia tubular esophagus , dysplasia cardia . To assess ability immunohistochemical ( IHC ) stain cardia tissue predict incident dysplasia cardia . Several well-characterized biomarkers , include p16 , p53 , Ki67 , cyclin D1 , cyclin A , assess .</brief_summary>
	<brief_title>Prevalence Dysplasia Gastric Cardia</brief_title>
	<detailed_description>This study consist cross-sectional arm , well prospective longitudinal arm , include patient undergoing ablative therapy UNC . The cross-sectional arm consist patient undergone ablative therapy Barrett 's Esophagus ( BE ) least one clear pathology report evidence Barrett 's Esophagus ( BE ) since first ablation . Concurrently enrol prospective longitudinal arm consist patient prior first ablation procedure . The prospective cohort follow 12 month long Barrett 's Esophagus ( BE ) yet clear 6 month initial treatment . Sampling gastric cardia clinical pathology become common patient receive received ablation therapy base evidence previous research suggest concern dysplasia gastric cardia . In group , research biopsy take top gastric fold ( TGF ) well gastric cardia ( TGF+1cm ) distal esophagus ( TGF-1 ) . Clinical biopsy consist standard esophageal biopsy distal esophagus well biopsy TGF , TGF+1cm TGF+2 cm . Clinical biopsy specimen fix review pathologist determine presence metaplastic , dysplastic , neoplastic change , per usual clinical practice . Research specimens undergo immunohistochemical ( IHC ) stain number biomarkers find positive patient dysplastic BE ( p16 , p53 , Ki67 , cyclin D1 , cyclin A ) . 1-4 Cross-sectional participant receive one-time study biopsy . Prospective longitudinal participant receive biopsy prior ablation therapy 6 12 month initial treatment . If Barrett 's Esophagus ( BE ) yet clear 6 month , biopsy take first endoscopy Barrett 's Esophagus ( BE ) clearance next clinically schedule follow-up visit .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<criteria>English speaking male female age 18 80 . Meet one follow : 1 . Individuals undergone ablation therapy dysplastic Barrett 's Esophagus ( BE ) intramucosal adenocarcinoma least one clear pathology report BE since first ablation ( crosssectional ) OR 2 . Individuals dysplastic Barrett 's Esophagus ( BE ) intramucosal adenocarcinoma undergo ablation therapy UNC first time ( prospective longitudinal ) Able read , comprehend , complete inform consent form . Bleeding disorder contraindication endoscopic biopsy . Current use blood thinner coumadin , warfarin , heparin and/or low molecular weight heparin ( require discontinuation medication 5 day prior 6 day Esophagogastroduodenoscopy ( EGD ) ) . History partial complete esophagectomy . Current diagnosis invasive esophageal cancer . Prior ablation cardia . Patients receive receive endoscopic mucosal resection ( EMR ) day enrollment gastric cardia distal esophagus , define top gastric fold ( TGF ) +2 centimeter top gastric fold 1 centimeter ( TGF+2 TGF1 ) . Prior EMR and/or EMR day enrollment area TGF+2 TGF1 OK . Pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Barrett 's Esophagus</keyword>
	<keyword>Intestinal metaplasia</keyword>
	<keyword>Intramucosal Adenocarcinoma</keyword>
	<keyword>Gastric Cardia</keyword>
	<keyword>High Cardia Dysplasia</keyword>
	<keyword>Radiofrequency ablation ( RFA )</keyword>
</DOC>